Clinical Trials
4,287 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT02231749 2026-05-27
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03388619 2026-05-27
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03570827 2026-05-26
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02710734 2026-05-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Completed
NCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04846920 2026-05-22
MK-6482-018
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05848011 2026-05-22
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
MacroGenics
Phase 2 Completed
NCT01823562 2026-05-20
Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT02397317 2026-05-19
SPARK
University of Sydney
Phase NA Completed
NCT03606837 2026-05-19
PROSTATEP
University Hospital, Bordeaux
Phase 2 Completed
NCT05146297 2026-05-19
DISRUPT
Icahn School of Medicine at Mount Sinai
Phase NA Completed
NCT00911118 2026-05-18
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT05410509 2026-05-18
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
University of Alabama at Birmingham
Phase NA Completed
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04019964 2026-05-15
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT01334073 2026-05-14
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT03470285 2026-05-14
IRMK01
University Hospital, Bordeaux
Phase NA Completed
NCT03604757 2026-05-14
UROPET
University Hospital, Bordeaux
Phase 2 Completed
NCT03644303 2026-05-14
TRAP
Royal Marsden NHS Foundation Trust
Phase NA Completed
NCT01624220 2026-05-12
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Phase NA Completed
NCT02761889 2026-05-12
Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer
Fundacao Champalimaud
Phase NA Completed
NCT03049410 2026-05-12
iROC
University College, London
Phase NA Completed
NCT04731844 2026-05-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Completed
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT06604442 2026-05-12
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
Phase 4 Completed
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04987203 2026-05-08
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT05114746 2026-05-08
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Completed
NCT07462403 2026-05-08
A Prolonged Nightly Fasting for Men on ADT for PCa
Thomas Jefferson University
Phase NA Completed
NCT02206334 2026-05-07
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
Phase 1 Completed
NCT03070886 2026-05-07
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT02535533 2026-05-06
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1/2 Completed
NCT03123978 2026-05-06
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
University of California, Davis
Phase 1 Completed
NCT04565457 2026-05-06
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
University of Colorado, Denver
Phase NA Completed
NCT04726319 2026-05-06
FHAMe
University of Toronto
Phase NA Completed
NCT05375539 2026-05-06
AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Milton S. Hershey Medical Center
Phase 1 Completed
NCT06575361 2026-05-06
Comprehensive Evaluation of MRI-AI in Prostate Cancer Diagnosis
Peking University First Hospital
Phase NA Completed
NCT07568444 2026-05-06
Enhancing Readability of Lay Abstracts and Summaries for Medical Knowledge Using Generative Artificial Intelligence (BRIDGE AI 3)
University of Southern California
Phase 2 Completed
NCT05005728 2026-05-05
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT06056505 2026-05-05
3DPN
University of Leipzig
Phase NA Completed
NCT07561502 2026-05-01
PERI III
Francis Medical Inc.
Phase NA Completed
NCT02649855 2026-04-29
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03218826 2026-04-29
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed